Lopinavir Cas:NO:192725-17-0

We are Lopinavir CAS:NO:192725-17-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Product Description

Product Name: Lopinavir CAS NO: 192725-17-0

 

Synonyms:

Koletr;

ABT 378;

Lopinavir;

Aluviran;

Koletra;;

1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[2-(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-α-(1-methylethyl)-2-oxo-, (αS)-;

(2S)-N-[(2S,4S,5S)-5-{[(2,6-Dimethylphenoxy)acetyl]amino}-4-hydroxy-1,6-diphenyl-2-hexanyl]-3-methyl-2-(2-oxotetrahydro-1(2H)-pyrimidinyl)butanamide;

 

Chemical & Physical Properties

Appearance : White to off-white Crystalline Solid

Assay : ≥99%

Density: 1.163±0.1 g/cm3

Boiling Point: 924.1°C at 760 mmHg

Flash Point: 512.7℃

Melting point:124-127℃

Solubility:DMSO: soluble20mg/mL, clear

 

Lopinavir, the sixth HIV protease inhibitor in the “navir” class, was launched in coformulation with ritonavir, another HIV protease inhibitor already marketed (Abbott, 1996); this original formulation was introduced as Kaletra for use in combination with either nucleoside or non-nucleoside reverse transcriptase inhibitors for the treatment of AIDS in adults and children. Lopinavir is a peptidomimetic compound with a structural core identical to that of ritonavir, on which terminal groups, particularly a modified valine, were introduced by peptide coupling procedures. Lopinavir is a potent competitive inhibitor of HIV-I protease exhibiting high potential against ritonavir-resistant mutations. In several animal species, pharmacokinetic studies with the lopinavirlritonavir association showed that the modest properties of lopinavir were significantly improved in presence of ritonavir, in terms of Cmax and duration of action. Ritonavir inhibits the P450 isoenzyme CYP3A4 and the human liver microsomal metabolism of lopinavir, so strongly amplifying plasma levels of this latter component. In AIDS patients, the plasma HIV RNA level was considerably reduced and the CD4+ T-cell counts increased after administration of lopinavir combined with relatively small doses of ritonavir. Kaletra is intended to be used jointly with other antiretroviral agents.

 

If you are interested in our products or have any questions, please feel free to contact us!

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.

Related Products:N-(1-(5-benzyl-3-methyl-4-oxo-4,5-dihydroisoxazolo[5,4-d]pyrimidin-6-yl)propyl)-N-(2-cyanoethyl)-3-methylbutanamide manufacturer | (14β,17α)-17-(hydroxymethyl)estr-5(10)-en-3-one supplier | 8-formyl-5-(4-nitrophenyl)-9H-1,3-dioxolo (4,5-h)(2,3)benzodiazepine producer.